2015, Number 4
Use of porcine surfactant in preterm newborns with early-onset bronchopneumonia
Language: Spanish
References: 25
Page: 348-356
PDF size: 564.50 Kb.
ABSTRACT
Background: there are disagreements about the use of surfactant in bronchopneumonia in newborns.Objective: to evaluate the behaviour of newborns with early bronchopneumonia treated with exogenous surfactant.
Methods: an open, multicentric, non-randomized or controlled study was conducted in 39 preterm newborns with early bronchopneumonia treated with exogenous surfactant. The gestation age, the birth weight and the stay time in the neonatal intensive care unit, the relation PaO2/FiO2, the mechanical ventilation time, the complications of ventilatory support and the mortality according to the number of doses of exogenous surfactant and the use of prenatal steroids were studied. The absolute and relative frequencies, the average and the chi-squared test were calculated.
Results: the need of administrating a greater number of doses was associated to a lower relation PaO2/FiO2 (p=0,0103). Adequate values were obtained with the first and the second doses. The use of prenatal steroids was associated to a lesser time with mechanical ventilation (p=0,0474), to greater values of the relation PaO2/FiO2(p=0,0162) and to a lower mortality (p=0,0076). No statistical association was found in the complications related to ventilation.
Conclusions: those patients who required a greater number of doses of surfactant had an unfavorable ventilatory response and a greater mortality. The use of prenatal steroids favoured a better ventilatory response and a lower mortality. The combination of prenatal steroids and exogenous surfactant can be beneficial in preterm newborns with early bronchopneumonia.
REFERENCES
Sarmiento Portal Y, Crespo Campos A, Portal Mi-randa ME, Morales Delgado I, Piloña Ruiz S. Aná-lisis de la morbilidad y mortalidad en recién naci-dos con peso inferior a 1 500 g. Rev Cubana Pe-diatr [Internet]. 2009 [citado 12 Sep 2012];81(4):[aprox 3 p.]. Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S003475312009000400002&lng=es&nrm=iso
Blanco Hidalgo O, Riverón Alemán Y, de Armas González E, Sánchez J, Faure García R, Fernán-dez Limia O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respirato-rias. Biotecnología Aplicada [Internet]. 2005 [citado 22 Dic 2013];22(4):[aprox 5 p.]. Disponible en: http://elfosscientiae.cigb.edu.cu/PDFs/Biotecnol%20Apl/2005/22/4/BA002204OC279-281.pdf
Blanco Hidalgo O, Lugones Ladrón de Guevara Y, Riverón Alemán Y, Núñez Drake A, Toraño Peraza G, Faure García R. Efecto antibacteriano de Surfacen® y la proteína A del surfactante pulmonar frente a un aislado clínico de Strepto-coccus pneumoniae. Rev Salud Anim [Internet]. 2014 [citado 22 Dic 2013];36(1):[aprox 4 p.]. Disponible en: http://scieloprueba.sld.cu/pdf/rsa/v36n1/rsa08114.pdf
Lopez E, Gascoin G, Flamant C, Merhi M, Tour-neux P, Baud O. Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?. BMC Pediatrics [Internet]. 2013 [citado 22 Dic 2013];13:[aprox. 5 p.]. Disponible en: http://www.biomedcentral.com/1471-2431/13/165
Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Surfactant for bacterial pneumonia in late pre-term and term infants [citado 2014 diciembre 15] [aprox. 4 p.]. Disponible en: http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=4997&id=CD008155&lang=es&dblang=&lib=COC
Moreno Vázquez O, Lee López M, Domínguez Dieppa F, Pascual López MA, Alonso Abad A, Jiménez Rivero G, Manzanares Tapia D. Estudio de la eficacia del Surfacen en el distress respira-torio del recién nacido. Rev Cubana Pediatr [Internet]. 1999 [citado 12 Ago 2014];71(2):[aprox. 11 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S00347531199900020002
Sánchez Mendiola M, Martínez Natera O, Herrera Maldonado N, Ortega Arroyo J. Estudio controla-do del tratamiento de la enfermedad de mem-brana hialina del recién nacido pretérmino con surfactante pulmonar exógeno (porcino vs. bo-vino). Gac Méd Méx [Internet]. 2005 [citado 12 Sep 2014];141(4):[aprox. 4 p.]. Disponible en: http://www.scielo.org.mx/scielo.php?pid=S001638132005000400003&script=sci_arttext&tlng=pt
Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Multiple versus single doses of exogenous surfactant for the prevention or treat-ment of neonatal respiratory distress syn-drome [citado 2014 enero 18] [aprox. 3 p.]. Disponible en: http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=4997&id=CD008155&lang=es&dblang=&lib=
Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Antenatal corticosteroids for acceler-ating fetal lung maturation for women at risk of preterm birth. [citado 2010 abril 30] [aprox. 3 p.]. Disponible en:http://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=2643&id=CD004454&lang=es&dblang=&lib=COC
Cochrane Database of Systematic Reviews [internet]. Cochrane: The Cochrane Library; 2009-. Repeat doses of prenatal corticoster-oids for women at risk of preterm birth for improving neonatal health outcomes. [citado 2014 agosto 12] [aprox. 3 p.]. Disponible en://cochrane.bvsalud.org/cochrane/show.php?db=reviews&mfn=2231&id=CD 003935&lang=es&dblang=&lib=COC
Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn JE. Antenatal steroids in preterm labour for the prevention of neonatal deaths due to compli-cations of preterm birth. Int J Epidemiol [Internet]. 2010 [cited 2013 Jul 1];39:[aprox 11 p.]. Disponible en: http://ije.oxfordjournals.org/content/39/suppl_1/i122.full.pdf+html